学位論文 von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.

Nishigori, Naoto  ,  Matsumoto, Masanori  ,  Koyama, Fumikazu  ,  Hayakawa, Masaki  ,  Hatakeyayama, Kinta  ,  Hatakeyama, Kinta  ,  Ko, Saiho  ,  Fujimura, Yoshihiro  ,  Nakajima, Yoshiyuki

10 ( 11 )  , p.e0143136 , 2015-11-18 , Public Library of Science
ISSN:19326203
内容記述
Oxaliplatin-based chemotherapy is widely used to treat advanced colorectal cancer (CRC). Sinusoidal obstruction syndrome (SOS) due to oxaliplatin is a serious type of chemotherapy-associated liver injury (CALI) in CRC patients. SOS is thought to be caused by the sinusoidal endothelial cell damage, which results in the release of unusually-large von Willebrand factor multimers (UL-VWFMs) from endothelial cells. To investigate the pathophysiology of CALI after oxaliplatin-based chemotherapy, we analyzed plasma concentration of von Willebrand factor (VWF) and the distribution of VWFMs in CRC patients. Twenty-three patients with advanced CRC who received oxaliplatin-based chemotherapy with (n = 6) and without (n = 17) bevacizumab were analyzed. CALI (n = 6) and splenomegaly (n = 9) were found only in patients who did not treated with bevacizumab. Plasma VWF antigen (VWF:Ag) and serum aspartate aminotransferase (AST) levels increased after chemotherapy only in patients without bevacizumab. VWFM analysis in patients who did not receive bevacizumab showed the presence of UL-VWFMs and absence of high molecular weight VWFMs during chemotherapy, especially in those with CALI. In addition, plasma VWF:Ag and AST levels increased after chemotherapy in patients with splenomegaly (n = 9), but not in patients without splenomegaly (n = 14). Histological findings in the liver tissue of patients who did not receive bevacizumab included sinusoidal dilatation and microthrombi in the sinusoids. Many microthrombi were positive for both anti-IIb/IIIa and anti-VWF antibodies. Plasma UL-VWFM levels might be increased by damage to endothelial cells as a result of oxaliplatin-based chemotherapy. Bevacizumab could prevent CALI and splenomegaly through inhibition of VWF-rich platelet thrombus formation.
博士(医学)・乙第1373号・平成28年3月15日
Copyright: © 2015 Nishigori et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
本文を読む

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3196/1/01%20%e4%b9%991373%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3196/2/02%20%e4%b9%991373%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3196/5/03%20%e4%b9%991373%e6%9c%ac%e6%96%87.pdf

このアイテムのアクセス数:  回

その他の情報